Overview

Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC

Status:
Enrolling by invitation

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

Lenvatinib Plus Hepatic Arterial Infusion of Modified FOLFOX Regime vs Lenvatinib Plus Hepatic Arterial Infusion of Oxaliplatin Plus Raltitrexed in Patients with Advanced Hepatocellular Carcinoma

Phase:

Early Phase 1

Details

Lead Sponsor:

Zhejiang Cancer Hospital

Collaborators:

First Affiliated Hospital of Wenzhou Medical University
First Affiliated Hospital of Zhejiang University
Jinhua Central Hospital
Second Affiliated Hospital of Wenzhou Medical University
Shaoxing People's Hospital
The Third Affiliated Hospital of Wenzhou Medical University

Treatments:

Fluorouracil
Lenvatinib
Leucovorin
Oxaliplatin
Raltitrexed